A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED, ASCENDING MULTIPLE DOSE STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF XMAB 5871 IN PATIENTS WITH RHEUMATOID ARTHRITIS

Trial Profile

A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED, ASCENDING MULTIPLE DOSE STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF XMAB 5871 IN PATIENTS WITH RHEUMATOID ARTHRITIS

Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Sep 2016

At a glance

  • Drugs XmAb 5871 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Xencor
  • Most Recent Events

    • 09 Nov 2015 According to a Xencor media release, data from this study were presented at the American College of Rheumatology (ACR) 2015 Annual Meeting.
    • 26 Jun 2015 According to a Xencor media release, data from this study were presented at the European League Against Rheumatism (EULAR) 2015 Annual Meeting.
    • 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top